National Institutes of Health

Invizyne specializes in the design of enzymes and construction of cell-free enzymatic pathways for continuous, unassisted biomanufacturing outside living cells.

Myosin Therapeutics is a biopharmaceutical company focused on developing novel medications that target cellular motor proteins. It leverages molecular machines that convert energy into mechanical work inside cells to create therapies aimed at treating central nervous system disorders and other diseases, including cancer. The company concentrates on advancing pharmacotherapies that modulate motor protein activity to impact disease pathways and address significant unmet medical needs.

Vast Therapeutics, Inc. is a preclinical-stage pharmaceutical company based in Durham, North Carolina, focused on developing inhalable treatments for antibiotic-resistant pathogens affecting patients with cystic fibrosis and other respiratory diseases. Established in 2017 and previously known as Novoclem Therapeutics, the company aims to address chronic infections that are prevalent in the cystic fibrosis population. Vast Therapeutics operates as a subsidiary of KNOW Bio, LLC, and is dedicated to advancing its innovative therapeutic solutions to improve health outcomes for patients facing these challenging conditions.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Sparian Biosciences is an early-stage biopharmaceutical company dedicated to the discovery and development of innovative therapies for the central nervous system (CNS). The firm specializes in creating unique and transformative medicines that specifically target brain-related conditions. Sparian is committed to advancing therapeutic solutions that address both acute and chronic pain through cutting-edge science and novel drug discovery methods.

Tiziana Life Sciences is a UK-based clinical-stage biotechnology company focused on discovering and developing novel molecules to treat diseases in oncology and immunology. Its pipeline includes Foralumab for autoimmune and inflammatory diseases, Milciclib for hepatocellular carcinoma, Anti IL-6r for severe COVID-19 symptoms, and StemPrintER for breast cancer diagnosis.

TransCode Therapeutics, founded in 2016 and based in Boston, Massachusetts, is a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative RNA therapeutics for treating metastatic cancer. Its lead therapeutic candidate targets an RNA molecule that drives metastatic disease across multiple tumor types.

Ensysce Biosciences is a clinical-stage biotechnology company developing safer prescription drugs using proprietary platforms. It focuses on creating abuse-resistant opioids and overdose-protection products to reduce addiction risks and accidental overdoses associated with traditional opioids.

Marker Therapeutics is a clinical-stage immuno-oncology company developing adoptive non-gene modified T cell therapies for treating hematologic malignancies. Its MultiTAA technology selectively expands non-engineered T cells to target and kill tumor cells expressing multiple tumor-associated antigens, preventing immune escape.

Anebulo Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapies for cannabinoid overdose and substance addiction. Its lead candidate, ANEB-001, is designed to reverse the effects of cannabinoid overdose within about one hour of administration. Early clinical data indicate rapid absorption and tolerability, with weight loss observed potentially linked to central cannabinoid receptor type 1 antagonism. The company aims to address acute overdose symptoms such as sedation, anxiety, panic, and psychosis by restoring balance to the endocannabinoid system.

Ensysce Biosciences is a clinical-stage biotechnology company developing safer prescription drugs using proprietary platforms. It focuses on creating abuse-resistant opioids and overdose-protection products to reduce addiction risks and accidental overdoses associated with traditional opioids.

Lamassu Pharma is a biotech startup developing small-molecule therapies for severe acute pancreatitis, with a lead candidate developed at Mayo Clinic that has shown strong preclinical results in reducing mortality and morbidity. The company is advancing this compound through safety testing in preparation for definitive clinical trials, aiming to deliver life-saving treatments to patients. In addition, Lamassu develops other small-molecule therapeutics targeting urgent medical needs, including potential cancer treatments, pursuing multiple candidates through clinical development. The organization emphasizes a patient-centric, evidence-based research approach to accelerate translation of science into therapies for unmet medical needs.

AcuraStem is a biotechnology company based in Monrovia, California, founded in 2016. The company specializes in developing a precision medicine platform that utilizes complex cellular models derived from Amyotrophic Lateral Sclerosis (ALS) patients' cells. AcuraStem employs advanced cellular reprogramming and artificial intelligence technologies to create patient-specific treatments for neurodegenerative diseases. Their platform is designed to evaluate disease progression and test existing therapeutics, as well as combinations of therapeutic approaches, to identify effective treatments that could slow disease progression. The company's team includes PhDs, professors, tech entrepreneurs, and veterans from the drug industry, all working towards addressing the challenges posed by ALS.

Amydis is a privately-held pharmaceutical company dedicated to developing innovative diagnostic tools for detecting diseases linked to amyloid protein deposits. Its core technology involves novel compounds that fluoresce upon binding to amyloid proteins, enabling non-invasive diagnosis. Amydis' primary focus is on early-stage Alzheimer's disease detection, with other potential applications including Parkinson's disease, Creutzfeldt-Jakob disease, and various forms of amyloidosis. The company aims to provide faster, more accessible, and affordable diagnostic solutions compared to existing methods, contributing to better healthcare decisions for patients and their families.

Hillhurst Biopharmaceuticals specializes in developing innovative, liquid therapeutic gases for treating sickle cell disease. Their core technology enables the oral delivery of low-dose carbon monoxide, targeting the protective heme oxygenase system to reduce inflammation, prevent cell death, and halt hemoglobin polymerization. This approach addresses challenges associated with traditional inhaled gas therapies, such as caregiver exposure and imprecise dosing, ensuring accurate and safe administration.

L2P Research Labs is a preclinical contract research organization (CRO) that specializes in providing comprehensive research and development support. The company offers a range of preclinical and toxicology services, utilizing advanced technologies such as quantitative whole-body animal imaging, small animal ultrasound, MRI, and CT scans. L2P Research Labs also provides proprietary orthotopic and metastatic tumor models, enabling researchers to access a complete suite of research services tailored to their needs. Through its innovative approaches and state-of-the-art facilities, the company supports the advancement of scientific research in the fields of medicine and drug development.

Rational Vaccines is a biotechnology company focused on developing vaccines for herpes simplex virus (HSV) and related diseases. It aims to revolutionize treatment, prevention, and diagnosis by creating rationally engineered, live-attenuated viral vaccines.

Integral Molecular, Inc. is a biotechnology company headquartered in Philadelphia, Pennsylvania, specializing in the development of innovative technologies for drug discovery targeting challenging diseases such as cancer, HIV, and arthritis. The company is particularly known for its Lipoparticle technology, which enhances the identification and optimization of drugs aimed at integral membrane proteins. With over 20 years of expertise in membrane proteins and antibodies, Integral Molecular has supported more than 400 pharmaceutical and biotechnology companies in their research, medication discovery, and vaccine development efforts. The company's solutions are integral to various stages of the drug discovery process, focusing on the development of chemical compounds and antibodies.

Clene Nanomedicine, established in 2012 and headquartered in Salt Lake City, Utah, is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for neurodegenerative diseases. The company has pioneered a unique nanotechnology drug platform that enables the creation of orally-administered neurotherapeutic drugs. This technology, known as Clean-Surface Nanosuspension, produces clean-surface nanocrystal medicines and serves as a foundation for a pipeline of new drug candidates aimed at addressing various diseases with significant unmet medical needs. Clene Nanomedicine's primary focus areas include demyelinating disorders and oncology.

Actinium Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for life-threatening diseases using its alpha particle immunotherapy platform. Its lead product candidates include Iomab-B, in Phase III trials as an induction agent for elderly AML patients prior to bone marrow transplant, and Actimab-A, in Phase II trials for newly diagnosed AML patients aged 60 and over.

Neurodon Corporation is a biopharmaceutical company focused on discovering and developing disease-modifying therapeutic candidates for intractable diseases. Established in 2019 and headquartered in Crown Point, Indiana, Neurodon specializes in molecular therapies that address endoplasmic reticulum (ER) stress, a significant factor in cell dysfunction and death. The company's innovative approach aims to restore calcium homeostasis through first-in-class modulators, addressing conditions such as Alzheimer's disease, Parkinson's disease, Huntington's disease, diabetes, and other rare diseases. Neurodon has made significant progress, with two candidates currently in IND-enabling studies and plans to enter clinical trials in 2025. The company has raised over $11 million through various funding sources, including state and federal grants, partnerships, and angel investments, and is actively seeking additional funding to support its first human studies for diabetes and rare disease programs.

Golden Helix is a developer of bioinformatics solutions specializing in genomic data analysis, with a focus on supporting life science research and translational medicine. With over 20 years of experience, the company provides innovative cloud-based software that empowers scientists and healthcare professionals to manage, analyze, and visualize complex genomic and phenotypic data. By streamlining the annotation and filtering of variants from next-generation sequencing, Golden Helix enables biologists and researchers of varying expertise to conduct intricate analyses and produce meaningful insights from large genomic datasets without the constant need for specialized bioinformatics support.

South Rampart Pharma is a clinical-stage biotechnology company focused on safer pain therapies. It develops synthesized, non-opioid and non-liver-toxic molecules that modulate pain signaling in the brain's periaqueductal gray (PAG) region, aiming to provide effective analgesia with reduced abuse potential and liver toxicity compared with traditional opioids. The company’s approach seeks to address key safety and tolerability challenges in current pain medicines while delivering meaningful relief for patients.

Strykagen manufactures transforming diagnostics and therapeutics for life-threatening rare muscle diseases.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance the understanding of human biology and diseases. Recognizing that while DNA offers valuable biological insights, it is proteins that provide critical information about bodily functions, Glyphic Biotechnologies is creating a next-generation sequencing technology. This innovative platform is designed to increase binding affinity and improve consistency, ultimately facilitating the creation of personalized and precision cancer vaccines for diverse patient populations. By enabling scientists and researchers to perform single-molecule, massively parallel protein sequencing, the company aims to support the development of novel therapeutics and diagnostics, paving the way for significant advancements in biomedical research and healthcare.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance the understanding of human biology and diseases. Recognizing that while DNA offers valuable biological insights, it is proteins that provide critical information about bodily functions, Glyphic Biotechnologies is creating a next-generation sequencing technology. This innovative platform is designed to increase binding affinity and improve consistency, ultimately facilitating the creation of personalized and precision cancer vaccines for diverse patient populations. By enabling scientists and researchers to perform single-molecule, massively parallel protein sequencing, the company aims to support the development of novel therapeutics and diagnostics, paving the way for significant advancements in biomedical research and healthcare.

Greenstone Biosciences is a drug discovery platform focused on accelerating the development of effective therapies for patients. By leveraging advanced technologies, including artificial intelligence and human-induced pluripotent stem cells, the company aims to transform the traditional drug discovery process, which is often slow and prone to high failure rates. Greenstone Biosciences seeks to create a rapid and integrated computational platform that can efficiently deliver safe and effective therapeutics, addressing diseases with significant unmet medical needs. Through its innovative approach, the company is dedicated to improving patient outcomes and advancing therapeutic options.

Spinogenix is a biopharmaceutical company focused on neurorestorative therapeutics that aim to restore brain connections and functions lost after brain injury and in neurodegenerative or psychiatric diseases. Founded in 2016 and based in San Diego, California, Spinogenix develops a new class of therapies designed to regenerate synapses and reverse declines in cognitive and motor function. The company targets direct modulation of synaptic proteins to rebuild neural connectivity, with the goal of reversing synapse loss and improving neurological outcomes. Therapies may be used as monotherapy or in combination with other treatments to address disease-specific degenerative processes, aiming to restore neural networks disrupted by CNS injury and degeneration.

Boston Immune Technologies & Therapeutics, Inc. is a biopharmaceutical company focused on developing immune-based therapies for cancer and infectious diseases. Incorporated in 2011 and located in Winchester, Massachusetts, the company has created a platform that targets the tumor necrosis factor receptor 2 (TNFR2) oncogene and the specific population of TNFR2 regulatory T cells within the tumor microenvironment. This innovative approach aims to enhance immunotherapy strategies, particularly for chronic infectious diseases, by leveraging the body's immune system to combat various health challenges.

Curi Bio is a biotechnology company dedicated to enhancing drug discovery and development through innovative technologies that leverage human stem cells, systems biology, and data analytics. The company aims to streamline the identification and development of new medicines by providing advanced biosystem platforms that integrate human cells and data. Curi Bio's technology offers a range of products designed for cell and tissue engineering, drug discovery, disease modeling, and fundamental cell biology research. By enabling in vivo maturation and alignment of various cell types, the company allows drug developers to conduct more accurate safety and efficacy tests on new drug candidates, ultimately fostering the advancement of next-generation human medicines.

Talus Bio is a biotechnology company specializing in drug discovery. It focuses on developing therapies targeting challenging cancer transcription factors using its proprietary MARMOT platform, which integrates functional proteomics, automated biology, machine learning, AI, synthetic chemistry, and computational biology to design and analyze drugs, proteins, and genomics.

The University of Utah, located in Salt Lake City, is the state's foremost public university and the only institution in Utah with a medical school. It offers a diverse array of undergraduate and graduate programs, encompassing over 100 undergraduate majors across disciplines such as architecture, business, education, engineering, fine arts, health careers, humanities, and social work, as well as more than 90 graduate degrees. In addition to its medical school, the University hosts a law school and a pharmacy school. Students are encouraged to engage in vibrant campus life through more than 400 clubs and organizations, alongside recreational activities and cultural events. Admission requirements include an application fee, transcripts, and standardized test scores, with a minimum high school GPA of 2.6. Financial aid is available based on both academic merit and financial need, with students required to complete the FAFSA to determine their eligibility for scholarships, loans, and grants.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance the understanding of human biology and diseases. Recognizing that while DNA offers valuable biological insights, it is proteins that provide critical information about bodily functions, Glyphic Biotechnologies is creating a next-generation sequencing technology. This innovative platform is designed to increase binding affinity and improve consistency, ultimately facilitating the creation of personalized and precision cancer vaccines for diverse patient populations. By enabling scientists and researchers to perform single-molecule, massively parallel protein sequencing, the company aims to support the development of novel therapeutics and diagnostics, paving the way for significant advancements in biomedical research and healthcare.

Applied BioMath, LLC, established in 2013 and headquartered in Concord, Massachusetts, specializes in systems biology and pharmacology services aimed at accelerating drug research and development for biotechnology and pharmaceutical companies. The company employs advanced mathematical modeling and simulation techniques to provide predictive guidance and insights throughout the drug discovery process. Its offerings include pathway model development, target and biomarker discovery, and feasibility assessments for various drug targets. Additionally, Applied BioMath conducts analyses of competitor compounds and projects drug properties and dosing for clinical phases. The firm utilizes proprietary algorithms and high-performance computational biology to optimize decision-making and mitigate risks associated with late-stage attrition in drug development. With additional offices in Cambridge and Oakland, Applied BioMath collaborates strategically with industry leaders such as Sanofi and Xilio Therapeutics to enhance its service offerings.

iMetabolic Biopharma is an early-stage precision medicine drug development company focused on obesity-related diseases. It develops therapeutics using its iPlatform technology, a platform designed to accelerate drug discovery and reduce development costs, enabling potential life-saving solutions to reach the clinic faster and more affordably.

Advent Therapeutics specializes in developing therapies for micro-orphan indications, focusing on unmet medical needs in neonatal and pediatric patient populations. Based in Lumberville, Pennsylvania.

Kintara Therapeutics is a clinical-stage cancer drug development company focused on creating and advancing therapies for difficult-to-treat cancers. Its late-stage product candidates include VAL-083, a DNA-targeting chemotherapeutic agent in Phase III-ready development for drug-resistant solid tumors such as glioblastoma multiforme, and REM-001, a photodynamic therapy for cutaneous metastatic breast cancer. The company pursues strategic collaborations to expand access, including a partnership with Guangxi Wuzhou Pharmaceutical to manufacture and sell VAL-083 in China. By focusing on streamlined, high-need cancer indications, Kintara aims to bring novel treatments to patients with limited options.

The University of Alabama at Birmingham (UAB), established in 1969, is a distinguished institution located in Birmingham, Alabama. It offers a diverse range of over 130 undergraduate and graduate programs, including degrees in the arts, sciences, business, education, engineering, and public health. UAB is particularly renowned for its medical school, which encompasses one of the largest university medical centers in the United States. The university has produced numerous scholars and award recipients, such as Fulbright, Rhodes, and Truman scholars, reflecting the high caliber of its education. Student life at UAB is dynamic, featuring more than 150 student organizations, an active Greek community, and a top-ranking recreation and fitness center, alongside year-round intramural sports. Most students reside in on-campus housing, and UAB provides financial aid and departmental fellowships to support those in need of tuition assistance. Through its commitment to education, research, and community service, UAB addresses both local and global challenges while fostering a culture of discovery and innovation.

The University of Utah, located in Salt Lake City, is the state's foremost public university and the only institution in Utah with a medical school. It offers a diverse array of undergraduate and graduate programs, encompassing over 100 undergraduate majors across disciplines such as architecture, business, education, engineering, fine arts, health careers, humanities, and social work, as well as more than 90 graduate degrees. In addition to its medical school, the University hosts a law school and a pharmacy school. Students are encouraged to engage in vibrant campus life through more than 400 clubs and organizations, alongside recreational activities and cultural events. Admission requirements include an application fee, transcripts, and standardized test scores, with a minimum high school GPA of 2.6. Financial aid is available based on both academic merit and financial need, with students required to complete the FAFSA to determine their eligibility for scholarships, loans, and grants.

Marker Therapeutics is a clinical-stage immuno-oncology company developing adoptive non-gene modified T cell therapies for treating hematologic malignancies. Its MultiTAA technology selectively expands non-engineered T cells to target and kill tumor cells expressing multiple tumor-associated antigens, preventing immune escape.

Aphios Corporation is a biotechnology company based in Woburn, Massachusetts, specializing in drug delivery platforms and the development of quality-of-life medicines. The company focuses on enhancing drug discovery and manufacturing through its innovative biotechnology and nanotechnology solutions. Aphios offers a range of therapeutic products aimed at health maintenance, disease prevention, and the treatment of various conditions, including cancers, infectious diseases, and central nervous system disorders. Notable products include Zindol, a ginger-based product, and various formulations of Taxotere for cancer treatment, which aim to improve oral bioavailability and target specific cancer cells. In addition to its therapeutic offerings, Aphios develops advanced technologies such as SuperFluids for pharmaceutical manufacturing and virology testing services, contributing to the safety and efficacy of drug therapies. Founded in 1993, Aphios continues to push the boundaries of medical science with its focus on innovative solutions for complex health challenges.

The University of Alabama at Birmingham (UAB), established in 1969, is a distinguished institution located in Birmingham, Alabama. It offers a diverse range of over 130 undergraduate and graduate programs, including degrees in the arts, sciences, business, education, engineering, and public health. UAB is particularly renowned for its medical school, which encompasses one of the largest university medical centers in the United States. The university has produced numerous scholars and award recipients, such as Fulbright, Rhodes, and Truman scholars, reflecting the high caliber of its education. Student life at UAB is dynamic, featuring more than 150 student organizations, an active Greek community, and a top-ranking recreation and fitness center, alongside year-round intramural sports. Most students reside in on-campus housing, and UAB provides financial aid and departmental fellowships to support those in need of tuition assistance. Through its commitment to education, research, and community service, UAB addresses both local and global challenges while fostering a culture of discovery and innovation.

Sensor-Kinesis Corporation develops innovative medical devices focused on pathogen and virus detection. Founded in 2013 and based in Los Angeles, the company is advancing proprietary biosensor technology that integrates flexible micro biosensor chips with computer systems. These chips are designed to detect specific biomolecules and can be printed on various surfaces, enabling widespread application across multiple industries, including healthcare, food safety, and pharmaceuticals. By linking these sensors to smart devices, users can transmit and analyze biological signals in real time, facilitating improved health monitoring. Sensor-Kinesis aims to empower healthcare professionals and individuals with affordable, portable devices that provide enhanced detection capabilities for diseases and health-related risks, promoting better health outcomes and safety.

TransCode Therapeutics, founded in 2016 and based in Boston, Massachusetts, is a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative RNA therapeutics for treating metastatic cancer. Its lead therapeutic candidate targets an RNA molecule that drives metastatic disease across multiple tumor types.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Founded in 1998, Second Sight is a medical device company dedicated to developing implantable visual prosthetics. Their primary product, the Argus II Retinal Prosthesis System, is designed to provide artificial vision to individuals blinded by outer retinal degenerations such as Retinitis Pigmentosa.

OncoSpherix, Inc., based in Atlanta, Ga, is a pre-clinical stage oncology drug development company that is advancing a proprietary platform of first-in-class small molecule therapeutics that are designed to improve the quality of life and survival for people with many forms of cancer by targeting a common feature of solid tumors: the activation of hypoxia inducible factor-1 (HIF-1). Nearly all solid cancers grow faster than their blood supply, leading to regions of low oxygen in the tumors and HIF activation. The HIFs in turn induce the expression of over 100 genes that help tumor cells survive and spread. OncoSpherix has several classes of small molecules that block activation of HIF-1 through novel mechanisms. OncoSpherix’s lead clinical candiate has been shown in mouse models to reduce primary tumor growth, inhibit metastases, and prolong survival in many types of cancer (glioblastoma, pancreatic cancer, uveal melanoma, lung cancer, breast cancer). Importantly, the agents are well tolerated and can be combined with therapeutics that work in well oxygenated regions of cancers, leading to dramatically enhanced cancer control.

Dignify Therapeutics is a drug development company based in Raleigh, North Carolina. Founded in 2013, it focuses on restoring voluntary control of bladder and bowel functions for patients with spinal cord injury, spina bifida, multiple sclerosis, and other neurological conditions through novel pharmaceutical agents.

PharmaJet develops and markets needle-free jet injectors for vaccine delivery, enabling administration without a needle and reducing sharps injuries, needle reuse, cross-contamination, and medical waste. Its Stratis and Tropis platforms are designed to deliver vaccines intramuscular, subcutaneous, or intradermal across various volumes, offering a potential return on investment by lowering risk and waste. Founded in 2005 and based in Golden, Colorado, PharmaJet focuses on delivering safe, user-friendly devices that support immunization programs and aim to simplify injections while expanding access to vaccination.

Aptinyx Inc. is a clinical-stage biopharmaceutical company based in Evanston, Illinois, that specializes in discovering and developing innovative therapies for disorders of the brain and nervous system. Founded in 2015, the company focuses on proprietary synthetic small molecules that modulate the NMDA receptor, enhancing nerve cell communication. Aptinyx's pipeline includes NYX-2925, which is in Phase II clinical development for painful diabetic peripheral neuropathy and fibromyalgia, and NYX-783, currently in Phase I trials for post-traumatic stress disorder. Additionally, NYX-458, another NMDA receptor modulator, is undergoing Phase I studies aimed at treating cognitive impairment associated with Parkinson's disease. The company also collaborates with Allergan plc to develop a compound for major depressive disorder, highlighting its commitment to addressing significant unmet medical needs in the central nervous system arena.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Evaxion Biotech is a clinical-stage company leveraging AI-immunology™ technology to decode the human immune system, developing novel immunotherapies for cancer and infectious diseases. Its pipeline includes three patient-specific cancer therapies in Phase I/IIa trials and vaccines targeting bacterial and viral infections.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance the understanding of human biology and diseases. Recognizing that while DNA offers valuable biological insights, it is proteins that provide critical information about bodily functions, Glyphic Biotechnologies is creating a next-generation sequencing technology. This innovative platform is designed to increase binding affinity and improve consistency, ultimately facilitating the creation of personalized and precision cancer vaccines for diverse patient populations. By enabling scientists and researchers to perform single-molecule, massively parallel protein sequencing, the company aims to support the development of novel therapeutics and diagnostics, paving the way for significant advancements in biomedical research and healthcare.

iQure Pharma is a global biotechnology company founded by entrepreneurs and former pharmaceutical industry managers. It specializes in the development of new therapeutics, focusing on neurodegenerative diseases with unmet medical needs.

Pantherics is a new type of therapy based on modulation of peripheral GABAA receptors.

Immuto Scientific offers biotechnology services, specializing in analytical insights for pharmaceutical companies during drug discovery. Its core technology automates complex protein analysis, expediting the determination of protein structures compared to industry standards.

Founded in 2006, Oligomerix is a biopharmaceutical company dedicated to developing therapeutics for Alzheimer's and related neurodegenerative diseases. It focuses on tau oligomer and tau protease inhibitor programs for small molecule drug discovery, and develops antibody fragments for tau oligomers as biomarkers.

Founded in 1998, Second Sight is a medical device company dedicated to developing implantable visual prosthetics. Their primary product, the Argus II Retinal Prosthesis System, is designed to provide artificial vision to individuals blinded by outer retinal degenerations such as Retinitis Pigmentosa.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Reliant Glycosciences is a biotechnology company dedicated to developing diagnostic and prognostic tools specifically for patients with IgA nephropathy. The company focuses on creating assays that identify biomarkers associated with this condition, which possess diagnostic and prognostic value. By characterizing disease-specific biomarkers, Reliant Glycosciences aims to facilitate the development and testing of innovative, targeted therapies for IgA nephropathy. This approach not only supports the advancement of transformative treatments but also enhances the overall understanding of the disease, ultimately benefiting patients affected by this condition.

AVM Biotechnology is a Seattle-based clinical-stage biotechnology company focused on regenerative medicine, oncology, and human biologics. It develops stem cell–based technologies and biologic therapies, including in-house compounds to modulate stem cell binding for enhanced organ regeneration and immune recovery, as well as platforms for personalized biologics that reduce immunogenicity and improve biodistribution. The Boutique Biologics platform supports patient-specific manufacturing approaches, while the Better Biologics platform provides methods for large-scale production of human biologics and aims to overcome resistance seen with non-human cell systems. The company also pursues preclinical programs, including repurposed small molecules and antibodies, and aims to provide cell lines for large-scale biologic production and patient-specific cell lines for personalized medicine. Led by oncology and immunology experts, AVM Biotechnology concentrates on translating stem cell and immune-based strategies to treat cancer, autoimmune diseases, and infectious diseases.

Founded in 2013, Immunicom specializes in developing innovative, non-pharmaceutical immunotherapy treatments for cancer, inflammatory diseases, and autoimmune disorders. The company's core product is a therapeutic device designed to filter blood and directly target various types of cancer, potentially enhancing the effects of other treatments with fewer side effects.

Talus Bio is a biotechnology company specializing in drug discovery. It focuses on developing therapies targeting challenging cancer transcription factors using its proprietary MARMOT platform, which integrates functional proteomics, automated biology, machine learning, AI, synthetic chemistry, and computational biology to design and analyze drugs, proteins, and genomics.

NovoMedix is a biotechnology company focused on developing novel orally available small molecules to address fibrotic disorders and certain cancer types. The company utilizes a proprietary technology platform that includes a library of small-molecule inhibitors, which have demonstrated significant efficacy in animal models for both fibrosis and cancer. Notably, some of these compounds co-target pathways that offer cardioprotective benefits and enhance the effectiveness of standard chemotherapies for triple negative breast cancer. This dual action aims to improve patient responses to treatment while significantly reducing the cardiotoxic effects commonly associated with chemotherapies, such as doxorubicin. As cardiovascular disease is a leading cause of death among breast cancer survivors, NovoMedix's approach prioritizes long-term patient health by addressing both cancer and associated heart risks. The company is working towards initiating IND enabling studies for its lead candidate, with the objective of delivering a safe and effective therapy to patients as soon as possible.

Modality.AI, Inc. is a healthcare technology company based in San Francisco, California, founded in 2018. It specializes in AI-powered solutions that enhance the efficiency of clinical trials for neurological and mental health therapies. The company's platform utilizes conversational AI to engage patients through naturalistic spoken interaction, allowing for continuous health assessments anytime and anywhere. By analyzing multimodal data, including audio-visual biomarkers, Modality.AI provides objective measures that correlate with clinical outcomes. This innovative approach enables pharmaceutical companies to conduct self-driven assessments and improve the monitoring of health conditions, ultimately facilitating more effective clinical trials.

PostEra is a Santa Clara, California-based company that provides AI-driven drug discovery and medicinal chemistry services. It develops machine learning models to design candidate molecules, predict bioactivity in low-data settings, and optimize synthetic routes to address chemo-, regio-, and stereo-selectivity in chemical reactions. The company offers an integrated platform that iteratively refines drug candidates, designs synthesis pathways, and guides experimental testing to accelerate biopharma programs. It collaborates with biopharma partners and pursues its own internal drug discovery efforts, including partnerships with Amgen, Pfizer, and the NIH. PostEra contributed to COVID Moonshot, a large open-science drug discovery initiative, illustrating its emphasis on open collaboration.

Founded in 1996, Simulations Plus develops Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) and Physiologically-Based Pharmacokinetic (PBPK) modeling software for the pharmaceutical industry. Its software aids in predicting key endpoints, reducing R&D costs, and supporting better project decisions. With over 60 employees, Simulations Plus serves major pharmaceutical companies and regulatory agencies worldwide.

Meridian Bioscience is an integrated life science company that develops, manufactures, and distributes clinical diagnostic test kits for gastrointestinal, viral, respiratory, and parasitic infectious diseases. The company specializes in molecular and immunological reagents, providing tools that support the discovery and diagnosis of various medical conditions. In addition to diagnostic test kits, Meridian offers bulk antigens, antibodies, PCR and qPCR reagents, nucleotides, and bioresearch reagents, serving researchers and other diagnostic manufacturers. Moreover, the company engages in contract development and manufacturing of proteins and other biologicals under cGMP conditions, catering to biopharmaceutical and biotechnology firms involved in drug and vaccine research. Meridian operates through three segments: U.S. Diagnostics, European Diagnostics, and Life Science, emphasizing its commitment to enhancing healthcare outcomes through innovative solutions.

Novoron Bioscience develops therapeutic approaches aimed at repairing damage and treating diseases of the central nervous system. The company concentrates on lipoprotein receptor biology to create CNS therapies, with preclinical programs addressing Alzheimer's disease and other tauopathies, multiple sclerosis, spinal cord injury, and related demyelinating conditions. Its platform explores both whole-receptor and micro-domain LDL receptor pathways to enable neuroprotection and recovery from CNS injury. Based in San Diego, Novoron Bioscience pursues novel biologics and agents intended to advance treatment options where current therapies are limited.

Delpor is a San Francisco-based developer of drug delivery technologies focused on creating sustained and pattern-specific release of proteins, peptides, and small molecules through small, non-mechanical subcutaneous implants. Its platforms include Prozor, a non-mechanical implantable device for delivering antipsychotics and other small molecules; NANOPOR, a membrane architecture-based implant offering prolonged release; and Delos PUMP, a self-contained implant that delivers drugs in programmed or pulse patterns, with potential for external activation to provide episodic dosing of therapies such as pain medications, antidotes, stimulants, or resuscitation agents. Founded in 2009, the company aims to improve medication adherence, safety, and efficacy by enabling convenient in-office implantation and simple administration, reducing the need for frequent injections. Delpor seeks to partner or license its technologies to advance long-acting formulations and pattern-specific dosing across therapeutic areas.

The University of Alabama at Birmingham (UAB), established in 1969, is a distinguished institution located in Birmingham, Alabama. It offers a diverse range of over 130 undergraduate and graduate programs, including degrees in the arts, sciences, business, education, engineering, and public health. UAB is particularly renowned for its medical school, which encompasses one of the largest university medical centers in the United States. The university has produced numerous scholars and award recipients, such as Fulbright, Rhodes, and Truman scholars, reflecting the high caliber of its education. Student life at UAB is dynamic, featuring more than 150 student organizations, an active Greek community, and a top-ranking recreation and fitness center, alongside year-round intramural sports. Most students reside in on-campus housing, and UAB provides financial aid and departmental fellowships to support those in need of tuition assistance. Through its commitment to education, research, and community service, UAB addresses both local and global challenges while fostering a culture of discovery and innovation.

4E Therapeutics is focused on developing innovative therapies for chronic pain disorders, particularly neuropathic pain, which represents a significant unmet medical need. The company specializes in orally bioavailable MNK inhibitors that exhibit enhanced tissue specificity and pharmacokinetic profiles, demonstrating potent analgesic effects in various animal pain models. By targeting the activity of elF4E proteins, 4E Therapeutics aims to regulate pain-sensing neurons within the peripheral nervous system. In addition to neuropathic pain, the company is also engaged in discovering and developing compounds to address migraine and acute pain, positioning itself as a leader in the field of pain management.

InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of addiction disorders. Their lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the CNS. IXT-m200 has received US FDA Fast Track Designation, and is being studied in an ongoing Phase 2 proof-of-concept study (STAMPOUT; NCT03336866). They are also developing a novel vaccine (IXT-v100) against methamphetamine, which is in Preclinical Development.

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative cell and gene therapies aimed at curing hematologic cancers, solid tumors, and rare genetic diseases. The company’s pipeline includes gene therapy programs for rare genetic disorders and chimeric antigen receptor (CAR) T cell therapies targeting various malignancies. Notable developments include MB-107, a potential curative gene therapy for X-linked severe combined immunodeficiency, and several CAR T therapies such as MB-102 for acute myeloid leukemia, MB-106 for B-cell lymphomas, and programs targeting glioblastoma and solid tumors like breast and pancreatic cancers. Mustang Bio has established collaborations with institutions such as Nationwide Children’s Hospital and Beth Israel Deaconess Medical Center to advance its research initiatives. Founded in 2015 and headquartered in New York, the company operates as a subsidiary of Fortress Biotech, Inc.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, focused on developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. Established in 2014, the company utilizes synthetic amplifier technology to enhance the speed and complexity of antibiotic susceptibility testing, thereby significantly improving patient care. By facilitating the rapid selection of personalized antimicrobial therapies, SeLux aims to transform the management of infectious diseases, ultimately saving lives, reducing hospital stays, and combating the growing issue of antibiotic resistance through more targeted treatments.

Amplo Biotechnology is a biotechnology company developing adeno-associated viral therapies aimed at curing defects in neuromuscular junctions, with an initial focus on congenital myasthenic syndromes. Its lead program, AAV-Dok7, originated with a research team from the Institute of Medical Science at the University of Tokyo and is designed to be delivered via intravascular injection to trigger molecular events that address paralysis, breathing, and swallowing difficulties caused by neuromuscular junction defects.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Novoron Bioscience develops therapeutic approaches aimed at repairing damage and treating diseases of the central nervous system. The company concentrates on lipoprotein receptor biology to create CNS therapies, with preclinical programs addressing Alzheimer's disease and other tauopathies, multiple sclerosis, spinal cord injury, and related demyelinating conditions. Its platform explores both whole-receptor and micro-domain LDL receptor pathways to enable neuroprotection and recovery from CNS injury. Based in San Diego, Novoron Bioscience pursues novel biologics and agents intended to advance treatment options where current therapies are limited.

Amydis is a privately-held pharmaceutical company dedicated to developing innovative diagnostic tools for detecting diseases linked to amyloid protein deposits. Its core technology involves novel compounds that fluoresce upon binding to amyloid proteins, enabling non-invasive diagnosis. Amydis' primary focus is on early-stage Alzheimer's disease detection, with other potential applications including Parkinson's disease, Creutzfeldt-Jakob disease, and various forms of amyloidosis. The company aims to provide faster, more accessible, and affordable diagnostic solutions compared to existing methods, contributing to better healthcare decisions for patients and their families.

Omnix Medical focuses on developing and commercializing highly effective antibiotic agents targeting resistant bacterial infections. It aims to combat the growing threat of drug-resistant bacteria, improving global public health.

ImmunoBrain Checkpoint is a biopharmaceutical company developing disease-modifying immunotherapies for neurological disorders by targeting immune checkpoint pathways. Building on research from Prof. Michal Schwartz at the Weizmann Institute of Science, the company aims to modulate immune signals with antibodies to promote a neuroprotective immune cascade and address neurodegenerative proteinopathies, with potential applications in Alzheimer's disease and related dementias.

Tabula Rasa Healthcare, formerly known as CareKinesis, specializes in state-of-the-art medication management solutions that leverage technology, science, and services to enhance the quality of care, reduce costs, and mitigate risks associated with ineffective medication plans. Their innovative approach aims to optimize medication therapy for improved patient outcomes.

TransCode Therapeutics, founded in 2016 and based in Boston, Massachusetts, is a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative RNA therapeutics for treating metastatic cancer. Its lead therapeutic candidate targets an RNA molecule that drives metastatic disease across multiple tumor types.

Praxis Bioresearch is a privately-held biopharmaceutical company that specializes in the discovery and development of innovative prodrug stimulants aimed at treating various chronic neuropsychiatric and neurodegenerative disorders. The company's lead candidate, PRX-P4-003, is engineered to provide the established therapeutic benefits associated with existing stimulant medications while reducing the risk of intravenous abuse. Through its focused research and development efforts, Praxis Bioresearch seeks to address unmet medical needs in the field of neuropsychiatric treatment.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and located in Columbus, Ohio. The company specializes in developing immune-oncology and gene therapies aimed at addressing devastating and rare diseases. Cytonus employs a synthetic biology approach through its proprietary Cargocyte technology, which enables precision delivery of therapeutics and in vivo production of innovative treatments. By integrating AI-driven drug discovery methods, Cytonus is focused on creating first-in-class therapeutics to treat immune-related disorders effectively.

Inso Biosciences is an early-stage biotechnology company that develops microfluidic hardware platforms for genomic sample handling. The company's patented microfluidic technology enables high-efficiency processing of cellular material and the separation and isolation of cellular components, supporting genomic analysis and DNA sequencing workflows. Its platform aims to improve long-read DNA extraction, multiomic sample processing, and pathogen surveillance, enabling healthcare and biotech organizations to perform biological sample preparation with greater efficiency and accuracy.

AvantGen is a San Diego-based biotechnology company founded in 2006 with Therapeutic and Research & Diagnostic divisions. It focuses on therapeutic antibody discovery, humanization, affinity maturation and optimization to advance antibody-based therapies. The company employs a yeast display system, a large natural human antibody database and fully human antibody libraries to enable discovery and screening against specific disease targets. Its platform also includes cell engager technologies and methodologies for generating rabbit monoclonal antibodies, supporting collaborations with pharmaceutical and biotechnology companies. Through services, partnerships and licensing, AvantGen helps accelerate therapeutic development.

CaroGen Corporation is a biopharmaceutical company developing recombinant virus-like vesicles for vaccines against infectious diseases. Its platform technology enables the creation of vaccines targeting hepatitis B, C, influenza, and other viral agents.

GenNext Technologies is a company that specializes in providing instrumentation, software, and services tailored for structural biology researchers in the biopharmaceutical industry. It develops advanced Protein and Contract Research Footprinting Systems, aimed at enhancing the understanding of biopharmaceutical structure, interactions, folding, aggregation, and formulation. By offering these specialized products and services, GenNext Technologies supports pharmaceutical researchers in conducting advanced studies that accelerate biopharmaceutical development, ultimately improving therapeutic efficacy and safety. The company's focus on structural biology empowers clients in the biotechnology field to advance their research efforts effectively.

Visikol Inc. is a New Jersey-based company specializing in advanced drug discovery through innovative bio-imaging and bioinformatics solutions. The company develops and provides cutting-edge tissue clearing technology and 3D imaging tools that enhance the visualization of plant and biological specimens. Its flagship product, Visikol, enables researchers to conduct optical sectioning of plant tissues, facilitating the identification of adulterants and the assessment of sample quality and authenticity. In addition, Visikol offers a range of tissue clearing kits and reagents, including Visikol HISTO, which seamlessly integrate 3D imaging into existing tissue processing workflows. The company's services include end-to-end drug discovery offerings, such as 2D and 3D cell culture model development, in vitro screening, and digital pathology, all aimed at transforming biological tissues into high-resolution images and quantitative data sets for informed decision-making in research and development.

Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and located in Columbus, Ohio. The company specializes in developing immune-oncology and gene therapies aimed at addressing devastating and rare diseases. Cytonus employs a synthetic biology approach through its proprietary Cargocyte technology, which enables precision delivery of therapeutics and in vivo production of innovative treatments. By integrating AI-driven drug discovery methods, Cytonus is focused on creating first-in-class therapeutics to treat immune-related disorders effectively.

Avexegen Therapeutics Inc. is a development stage biotechnology company based in San Diego, California, founded in 2014. The company specializes in creating innovative therapies aimed at healing damaged and inflamed gut tissue in patients suffering from gastrointestinal disorders, particularly Crohn's disease and ulcerative colitis. Additionally, Avexegen focuses on addressing needs in premature infants with necrotizing enterocolitis. By employing a novel approach to treatment, Avexegen aims to improve the long-term health outcomes of patients with these serious conditions.

Meridian Bioscience is an integrated life science company that develops, manufactures, and distributes clinical diagnostic test kits for gastrointestinal, viral, respiratory, and parasitic infectious diseases. The company specializes in molecular and immunological reagents, providing tools that support the discovery and diagnosis of various medical conditions. In addition to diagnostic test kits, Meridian offers bulk antigens, antibodies, PCR and qPCR reagents, nucleotides, and bioresearch reagents, serving researchers and other diagnostic manufacturers. Moreover, the company engages in contract development and manufacturing of proteins and other biologicals under cGMP conditions, catering to biopharmaceutical and biotechnology firms involved in drug and vaccine research. Meridian operates through three segments: U.S. Diagnostics, European Diagnostics, and Life Science, emphasizing its commitment to enhancing healthcare outcomes through innovative solutions.

Coral Genomics, Inc. is a biotechnology company founded in 2018 and headquartered in San Francisco, California. The company focuses on optimizing drug development and deployment by leveraging genomic data from patients. It specializes in developing clinical tests that assist healthcare providers in streamlining prior authorization processes and selecting effective medications tailored to individual patients, particularly in the context of autoimmune conditions like Inflammatory Bowel Disease and Rheumatoid Arthritis. Additionally, Coral Genomics has identified a distinct group of non-responder patients and collaborates with pharmaceutical developers to address the unmet medical needs of this population. By measuring cell responsiveness to drugs and understanding variability across patients, Coral Genomics aims to enhance treatment strategies and improve patient outcomes.

Photonic Pharma is an early phase of drug development which uses a game-changing technology platform that combines breakthroughs in fluorescence biosensor engineering and fluorescence lifetime detection in living cells.

Soligenix, Inc., a late-stage biopharmaceutical company based in Princeton, New Jersey, focuses on developing and commercializing treatments for rare diseases and serious side effects of cancer therapies, where there is an unmet medical need. The company operates through two segments: Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops therapies such as SGX301 for cutaneous T-cell lymphoma, SGX942 for oral mucositis in head and neck cancer, and proprietary formulations of oral beclomethasone for gastrointestinal disorders. The Public Health Solutions segment works on biodefense vaccines and therapeutics, including RiVax, a ricin toxin vaccine, and SGX943, a therapeutic candidate for antibiotic-resistant and emerging infectious diseases.

Meridian Bioscience is an integrated life science company that develops, manufactures, and distributes clinical diagnostic test kits for gastrointestinal, viral, respiratory, and parasitic infectious diseases. The company specializes in molecular and immunological reagents, providing tools that support the discovery and diagnosis of various medical conditions. In addition to diagnostic test kits, Meridian offers bulk antigens, antibodies, PCR and qPCR reagents, nucleotides, and bioresearch reagents, serving researchers and other diagnostic manufacturers. Moreover, the company engages in contract development and manufacturing of proteins and other biologicals under cGMP conditions, catering to biopharmaceutical and biotechnology firms involved in drug and vaccine research. Meridian operates through three segments: U.S. Diagnostics, European Diagnostics, and Life Science, emphasizing its commitment to enhancing healthcare outcomes through innovative solutions.

Ocuphire Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for various ophthalmic disorders. Its lead product candidate, Nyxol eye drops, is a once-daily preservative-free formulation of phentolamine mesylate aimed at reducing pupil size for indications such as night vision disturbances, glaucoma, pharmacologically-induced mydriasis, and presbyopia.

Coda Biotherapeutics, Inc. is a biotechnology company focused on developing innovative therapies to modulate neuronal activity through its chemogenetic platform. Established in 2014 and based in San Francisco, the company employs gene therapy techniques to modify specific neuronal populations, enabling them to express engineered ligand-gated ion channels that are responsive to a proprietary small molecule. This interaction allows for precise, dose-dependent control of neuronal activity, facilitating the treatment of conditions such as neuropathic pain, epilepsy, and movement disorders. Coda's approach utilizes viral vectors to deliver these engineered neurotransmitter receptors directly to targeted neurons, enhancing the efficiency of treatment for severe nervous system disorders compared to traditional therapies.